111 related articles for article (PubMed ID: 36389684)
1. Combining all-trans retinoid acid treatment targeting myeloid-derived suppressive cells with cryo-thermal therapy enhances antitumor immunity in breast cancer.
Lou Y; Peng P; Wang S; Wang J; Du P; Zhang Z; Zheng J; Liu P; Xu LX
Front Immunol; 2022; 13():1016776. PubMed ID: 36389684
[TBL] [Abstract][Full Text] [Related]
2. Natural Killer Cells Reprogram Myeloid-Derived Suppressor Cells to Induce TNF-α Release via NKG2D-Ligand Interaction after Cryo-Thermal Therapy.
You J; Wang S; Zhu Y; Zhang Z; Wang J; Lou Y; Yao Y; Hao Y; Liu P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791188
[TBL] [Abstract][Full Text] [Related]
3. Th1-Dominant CD4
Peng P; Lou Y; Wang J; Wang S; Liu P; Xu LX
Front Immunol; 2022; 13():944115. PubMed ID: 35874660
[TBL] [Abstract][Full Text] [Related]
4. IFNγ at the early stage induced after cryo-thermal therapy maintains CD4
Wang J; Lou Y; Wang S; Zhang Z; You J; Zhu Y; Yao Y; Hao Y; Liu P; Xu LX
Front Immunol; 2024; 15():1345046. PubMed ID: 38827732
[TBL] [Abstract][Full Text] [Related]
5. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells.
Oh MH; Sun IH; Zhao L; Leone RD; Sun IM; Xu W; Collins SL; Tam AJ; Blosser RL; Patel CH; Englert JM; Arwood ML; Wen J; Chan-Li Y; Tenora L; Majer P; Rais R; Slusher BS; Horton MR; Powell JD
J Clin Invest; 2020 Jul; 130(7):3865-3884. PubMed ID: 32324593
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cells proliferation assay to analyze Mo-MDSCs suppressive function.
Iglesias-Escudero M; San Segundo D; López-Hoyos M
Methods Cell Biol; 2024; 184():69-84. PubMed ID: 38555159
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression.
Colligan SH; Amitrano AM; Zollo RA; Peresie J; Kramer ED; Morreale B; Barbi J; Singh PK; Yu H; Wang J; Opyrchal M; Sykes DB; Nemeth MJ; Abrams SI
J Clin Invest; 2022 Dec; 132(23):. PubMed ID: 36453551
[TBL] [Abstract][Full Text] [Related]
8. Adoptively Transferred in vitro-Generated Myeloid-Derived Suppressor Cells Improve T-Cell Function and Antigen-Specific Immunity after Traumatic Lung Injury.
Kustermann M; Dasari P; Knape I; Keltsch E; Liu J; Pflüger S; Osen W; Holzmann K; Huber-Lang M; Debatin KM; Strauss G
J Innate Immun; 2023; 15(1):78-95. PubMed ID: 35691281
[TBL] [Abstract][Full Text] [Related]
9. Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy.
Sarkar OS; Donninger H; Al Rayyan N; Chew LC; Stamp B; Zhang X; Whitt A; Li C; Hall M; Mitchell RA; Zippelius A; Eaton J; Chesney JA; Yaddanapudi K
Sci Adv; 2023 Jun; 9(26):eadg3736. PubMed ID: 37390211
[TBL] [Abstract][Full Text] [Related]
10. Targeting miR-223 enhances myeloid-derived suppressor cell suppressive activities in multiple sclerosis patients.
Cantoni C; Ghezzi L; Choi J; Cross AH; Piccio L
Mult Scler Relat Disord; 2023 Aug; 76():104839. PubMed ID: 37364375
[TBL] [Abstract][Full Text] [Related]
11. Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy.
Nishibata T; Amino N; Tanaka-Kado R; Tsujimoto S; Kawashima T; Konagai S; Suzuki T; Takeuchi M
Biomed Res Int; 2023; 2023():7133726. PubMed ID: 38058393
[TBL] [Abstract][Full Text] [Related]
12. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion.
Lauder SN; Smart K; Bart VMT; Pires A; Scott J; Milutinovic S; Godkin A; Vanhaesebroeck B; Gallimore A
Br J Cancer; 2022 Nov; 127(9):1595-1602. PubMed ID: 35986086
[TBL] [Abstract][Full Text] [Related]
13. A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.
Shipp C; Speigl L; Janssen N; Martens A; Pawelec G
Cell Mol Life Sci; 2016 Nov; 73(21):4043-61. PubMed ID: 27236468
[TBL] [Abstract][Full Text] [Related]
14. Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis.
Hou Y; Zhang H; Zhu Y; He X; Li W; Su L; Liu M; Chen X; Shen F; Chen X; Jiang W; Zou C; Xu Z
Int Immunopharmacol; 2023 Oct; 123():110710. PubMed ID: 37531829
[TBL] [Abstract][Full Text] [Related]
15. Intermittent fasting suppressed splenic CD205+ G-MDSC accumulation in a murine breast cancer model by attenuating cell trafficking and inducing apoptosis.
Fu C; Lu Y; Zhang Y; Yu M; Ma S; Lyu S
Food Sci Nutr; 2021 Oct; 9(10):5517-5526. PubMed ID: 34646521
[TBL] [Abstract][Full Text] [Related]
16. A Metabolic Reprogramming Amino Acid Polymer as an Immunosurveillance Activator and Leukemia Targeting Drug Carrier for T-Cell Acute Lymphoblastic Leukemia.
Li C; You X; Xu X; Wu B; Liu Y; Tong T; Chen J; Li Y; Dai C; Ye Z; Tian X; Wei Y; Hao Z; Jiang L; Wu J; Zhao M
Adv Sci (Weinh); 2022 Mar; 9(9):e2104134. PubMed ID: 35080145
[TBL] [Abstract][Full Text] [Related]
17. The Functional Roles of MDSCs in Severe COVID-19 Pathogenesis.
Len JS; Koh CWT; Chan KR
Viruses; 2023 Dec; 16(1):. PubMed ID: 38257728
[TBL] [Abstract][Full Text] [Related]
18. LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
Gong L; Sun H; Liu L; Sun X; Fang T; Yu Z; Sui W; Xu J; Wang T; Feng F; Lei L; Rui W; Liu Y; Zhao X; An G; Lin X; Qiu L; Hao M
Haematologica; 2024 May; ():. PubMed ID: 38813706
[TBL] [Abstract][Full Text] [Related]
19. Bifunctional Janus Particles as Multivalent Synthetic Nanoparticle Antibodies (SNAbs) for Selective Depletion of Target Cells.
Liu J; Toy R; Vantucci C; Pradhan P; Zhang Z; Kuo KM; Kubelick KP; Huo D; Wen J; Kim J; Lyu Z; Dhal S; Atalis A; Ghosh-Choudhary SK; Devereaux EJ; Gumbart JC; Xia Y; Emelianov SY; Willett NJ; Roy K
Nano Lett; 2021 Jan; 21(1):875-886. PubMed ID: 33395313
[TBL] [Abstract][Full Text] [Related]
20. H
Li S; Xu F; Ren X; Tan L; Fu C; Wu Q; Chen Z; Ren J; Huang Z; Meng X
ACS Nano; 2023 Oct; 17(19):19242-19253. PubMed ID: 37781935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
